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Parasite resistance to antimalarial drugs is a serious threat to human health, and novel agents that act on
enzymes essential for parasite metabolism, such as proteases, are attractive targets for drug development.
Recent studies have shown that clinically utilized human immunodeficiency virus (HIV) protease inhibitors
can inhibit the in vitro growth of Plasmodium falciparum at or below concentrations found in human plasma
after oral drug administration. The most potent in vitro antimalarial effects have been obtained for parasites
treated with saquinavir, ritonavir, or lopinavir, findings confirmed in this study for a genetically distinct P.
falciparum line (3D7). To investigate the potential in vivo activity of antiretroviral protease inhibitors (ARPIs)
against malaria, we examined the effect of ARPI combinations in a murine model of malaria. In mice infected
with Plasmodium chabaudi AS and treated orally with ritonavir-saquinavir or ritonavir-lopinavir, a delay in
patency and a significant attenuation of parasitemia were observed. Using modeling and ligand docking studies
we examined putative ligand binding sites of ARPIs in aspartyl proteases of P. falciparum (plasmepsins II and
IV) and P. chabaudi (plasmepsin) and found that these in silico analyses support the antimalarial activity
hypothesized to be mediated through inhibition of these enzymes. In addition, in vitro enzyme assays demon-
strated that P. falciparum plasmepsins II and IV are both inhibited by the ARPIs saquinavir, ritonavir, and
lopinavir. The combined results suggest that ARPIs have useful antimalarial activity that may be especially
relevant in geographical regions where HIV and P. falciparum infections are both endemic.
Malaria is a major cause of morbidity and mortality, infect-
ing 300 to 500 million and killing an estimated 2 million people
annually (60). Three approaches to control the most important
malaria parasite, Plasmodium falciparum, are vaccine develop-
ment, vector control, and chemotherapy. An effective vaccine
has yet to be developed and must await a better understanding
of the targets for protective immunity, parasite antigenic vari-
ation, and the critical immune effector mechanisms. Vector
control through insecticide spraying programs has eradicated
the parasite from southern Europe, North America, and
Australia and has reduced transmission elsewhere. However,
vector ecology and rising insecticide resistance limit the effec-
tiveness of this approach. Since its discovery in the 1940s, the
4-aminoquinoline drug chloroquine has been the most widely
used antimalarial drug. However, the development of drug
resistance has dramatically reduced its effectiveness in most
regions where malaria is endemic (34), and resistance to other
antimalarials is also developing.
The recent completion of the P. falciparum genome se-
quence is now enabling the identification of novel drug targets,
and the increasing power of structure-based medicinal chem-
istry is facilitating rational drug design for as-yet-unexplored
parasite targets (58). One example of successful rational struc-
ture-based drug design is the clinical development of antiretro-
viral drugs that block the action of the aspartyl protease of the
human immunodeficiency virus (HIV) (1, 59). Two such anti-
retroviral protease inhibitors (ARPIs) have been reported to
reduce in vitro cytoadherence of P. falciparum-infected eryth-
rocytes to drug-exposed endothelial cells (37), a process linked
in vivo with parasite virulence. More recently, we and others
have reported that ARPIs have antiparasitic activity against P.
falciparum in vitro (40, 51). We now report the in vivo activity
of ARPI combinations at clinically relevant concentrations in a
rodent model of malaria, model putative binding of these com-
pounds in the enzyme active sites, and show in vitro inhibition
of three of these inhibitors against two recombinant P. falci-
parum aspartic proteases, plasmepsin II (PM-II) and PM-IV.
MATERIALS AND METHODS
P. falciparum growth in vitro. P. falciparum clone Dd2 and 3D7 parasites were
cultured in blood group O human erythrocytes and serum (55). Cultures were
maintained in a synchronous state by sorbitol treatment (30). In vitro growth
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inhibition of ring-stage-parasitized erythrocytes starting at 0.25% parasitemia
and 2.5% hematocrit was determined by [3H]hypoxanthine incorporation using
standard methods (2, 51). Ritonavir gel capsule formulation (Norvir; Abbott)
was prepared as a 20 mM stock in dimethyl sulfoxide (DMSO). The gel capsule
coformulation of ritonavir and lopinavir (Kaletra; Abbott) was prepared as a 20
mM stock based on the ritonavir concentration (92 mM lopinavir). Chloroquine
(chloroquine diphosphate salt; Sigma) was prepared as a 10 mM stock in phos-
phate-buffered saline and included in each assay as a control. In all assays, the
concentrations of DMSO and phosphate-buffered saline were maintained at
0.5%, concentrations that did not affect growth of control cultures (data not
shown). The concentration of drug that inhibited parasite growth by 50% (EC50)
was determined by linear interpolation of inhibition curves (26).
P. falciparum blood-stage development and hemoglobin digestion. To deter-
mine the in vitro effects of drugs on P. falciparum-parasitized erythrocytes, Dd2
ring-stage-parasitized erythrocytes were incubated for 20 h with 10 M E64,
pepstatin A, ritonavir, saquinavir (Fortivase; Roche), or atazanavir (Reyataz;
Bristol-Myers Squibb). In parallel controls, parasites were treated with an equiv-
alent concentration of drug solvent (DMSO) or 1 M chloroquine. Drug stocks
were prepared as 20 mM solutions in DMSO (final concentration of DMSO in
tests was 0.1%). After 20 h of growth in vitro, the morphology of drug-treated
parasites was compared to that of controls by microscopic examination of
Giemsa-stained thin blood smears. To determine the effect on hemoglobin di-
gestion, parasites were processed as previously described (44) and extracts were
electrophoresed via 15% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (5  106 parasites per lane), followed by staining with Coomassie blue.
Determination of drug concentrations in the plasma of mice. Drugs were
prepared from gel capsule formulations of saquinavir, ritonavir, and lopinavir-
ritonavir in a suspension that resembles ritonavir vehicle (Cremaphor EL [65
mg/ml; Sigma], propylene glycol [0.156 mg/ml], peppermint oil [2.18 mg/ml],
water-free citric acid [1.75 mg/ml], and 26.87% ethanol) (27). Groups of three
8-week-old female C57BL/6J mice each received a single 100-l oral gavage in a
dose ranging from 5 to 50 mg/kg body weight (average body weight,20 g). After
4 hours (29), mice were euthanized by CO2 exposure and blood was collected by
cardiac puncture. Plasma samples were stored at 20°C and transported over-
night on ice before analysis. Lopinavir and ritonavir plasma concentrations were
quantitated by high-performance liquid chromatography (HPLC) adapted from
a previously reported method (41). Plasma (0.5 ml) and standards were extracted
with 5.0 ml 1-chlorobutane. After mixing and centrifugation the organic solvent
was evaporated and the residue was resuspended in mobile phase (0.5 ml aceto-
nitrile:10 mM potassium phosphate buffer, pH 7.0; 50:50). The mobile phase was
washed twice with 3 ml 99% hexane, and 50 l was injected onto a phenyl hexyl
HPLC column (250  4.6 mm; 5 m) with UV detection at 205 nm. The
calibration standards ranged from 50 to 10,000 g/liter (r 0.999), and the lower
limit of detection was 25 g/liter. Precision was better than 6% relative standard
deviation, and accuracy was within 4% of the expected values for the assay.
Saquinavir plasma concentrations were quantitated by HPLC. Plasma (1.0 ml)
and standards were alkalinized with 500 l of 0.5 M sodium hydroxide and
extracted with 7.0 ml diethyl ether (analytical reagent grade; Lab-Scan). After
mixing and centrifugation and transfer to a new tube, the organic solvent was
evaporated and the residue was resuspended in 6.0 ml 95% n-hexane with brief
vortexing. Mobile phase (0.2 ml acetonitrile:25 mM sodium phosphate, pH 3.4;
42:58) was added to the 95% n-hexane and vortexed. After centrifugation the
organic phase was discarded and 80 l of the aqueous phase was transferred into
an autosampler. Separation was performed on a cyano column (150  4.6 mm;
5 m; Zorbax SB CN; Dupont) with UV detection at 239 nm. Calibration
standards ranged from 10 to 1,000 g/liter (r  0.999). Precision was better than
10% relative standard deviation, and accuracy was within 11% of the expected
values for the assay.
In vivo antimalarial studies. The in vivo antimalarial activity of ARPIs was
determined using the nonlethal murine malaria model of Plasmodium chabaudi
AS (52) in 8-week-old C57BL/6J female mice. Mice were housed in a reverse
light cycle cabinet (daylight, 10 p.m. to 10 a.m.), to ensure drug exposure during
the trophozoite stages. Groups of six mice (average weight, 20 g) were infected
intravenously in the tail vein with 105 parasitized erythrocytes from an infected
donor mouse. Drugs were prepared from gel capsule formulations, as described
in the previous section. Mice received drug in a 100-l oral solution twice a day
for 8 days, beginning 24 h postinfection (p.i.). Control groups received an equiv-
alent volume of vehicle alone twice a day for 8 days, beginning 24 h p.i., or
atovaquone-proguanil (Malarone; GlaxoSmithKline) at 0.2 mg/0.08 mg in 100 l
water orally once daily for 4 days (16), beginning 24 h p.i. Parasitemia was
monitored from day 4 p.i. by daily microscopic examination of Giemsa-stained
thin blood smears. Statistical analysis for differences in peak parasitemia between
treatment groups was undertaken using the nonparametric Mann-Whitney U rank
test. Animals were purchased from the Animal Resources Centre, Welleton,
Western Australia, Australia, and were housed in the Queensland Institute of
Medical Research (QIMR) animal facility under specific-pathogen-free condi-
tions. Ethical approval for all animal work was obtained from the QIMR Animal
Ethics Committee using protocols complying with guidelines set out by the
National Health and Medical Research Council of Australia Animal Code of
Practice.
Modeling studies. The sequence of P. chabaudi plasmepsin (PcPM) was ob-
tained from the SwissProt database, ID Q95V53. Structural coordinates of P.
falciparum PM-II (PfPM-II) and PfPM-IV were obtained from the Protein Data
Bank (PDB) database. Protein structures 1lf3 (PfPM-II) and 1ls5 (PfPM-IV)
were used for docking studies. A homology model of PcPM and PfPM-I was
developed using the modeler7v7 program and PfPM-II (1sme) as the template
and further optimized in InsightII. PM proteins were compared by sequence
and structural alignments using InsightII. Coordinates for amprenavir (1hpv),
nelfinavir (1ohr), saquinavir (1hxb), ritonavir (1hxw), indinavir (1hsg), lopinavir
(1mui), BR314 (1d4k), and BR124 (1d4l) bound to HIV type 1 (HIV-1) protease
were obtained from the PDB. Pepstatin A coordinates were obtained from the
complex with PfPM-II (1sme).
Docking studies were performed using Gold v2.1 on inhibitors containing
statine and hydroxyethylamine isosteres to gain insight into possible interactions
of these inhibitors with PfPM-II and PfPM-IV. Docking simulations were per-
formed on known ligand-enzyme crystal structures (PDB, 1lf3 and 1ls5) to
optimize structural constraints that generated the best docking ligand-enzyme
models, as deduced through comparison between modeled ligand structures and
protein-bound ligand-PM crystal structures. The optimal docking protocol was
FIG. 1. Structures of aspartyl protease inhibitors.
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then used to derive the ligand-enzyme complexes for HIV-1 protease inhibitors.
For each inhibitor, 10 independent docking experiments were performed. To
accelerate calculations, docking was stopped when a root mean square deviation
(RMSD) of 1.5 Å was reached for the three lowest-energy structures.
In one modeling protocol, a distance constraint (2.5 to 3.5 Å) was used
between the hydroxyl oxygen of the statine (or transition-state isostere) and the
two catalytic aspartate carboxylate oxygens of PfPM-II and PfPM-IV. A second
protocol was examined for comparison, with ligands also separately docked using
two additional hydrogen bond restraints (P2 carbonyl group to OH of Ser79, P1
carbonyl group to NH of Val78) on either side of the hydroxyl group of the
statine in PfPM-II and one additional hydrogen bond constraint from the P2
carbonyl group to the NH of Gly78 in PfPM-IV. This second protocol gave
results that more effectively matched the crystal structures, and so this was used
for docking HIV-1 protease inhibitors in PfPMs. All modeling and docking were
visualized in InsightII on Silicon Graphics R10000 and R12000 workstations.
Docked structures were inspected manually to assess their binding mode(s),
scored with GOLD, and then rescored using Ludi. The binding of substrates and
substrate-based inhibitors of proteases is heavily influenced by hydrogen bonding
networks. Ludi has been shown (9) to provide a well-developed analysis of
hydrogen bonding as a contribution towards overall binding energy.
Recombinant plasmepsin II and IV chromogenic assays. Recombinant plas-
mepsin II was prepared according to the method of Hill et al. (24), and recom-
binant plasmepsin IV was prepared according to the method of Wyatt and Berry
(61). Fifty percent inhibitory concentration (IC50) values for the interaction of
PM-II or PM-IV with protease inhibitors were calculated by monitoring the
cleavage of the synthetic peptide substrate KERVF*ZALK (for PM-II) or KPI
EF*ZRL (for PM-IV) (where * represents the scissile peptide bond and Z is
nitrophenyl alanine) at a final enzyme concentration of 40 nM (PM-II) or 25 nM
(PM-IV), in 100 mM sodium acetate buffer, pH 4.7 (with the ionic strength
maintained at 100 mM by the addition of sodium chloride), at differing inhibitor
concentrations. The final substrate concentration in the assay was at least three-
fold higher than the Km value, in order not to be rate-limiting. IC50 data were
calculated from standardized, multiple experiments for each inhibitor concen-
tration. The error on each data point was estimated to always be less than 15%.
Pure lopinavir used in these assays was obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH.
RESULTS
In vitro antimalarial activity. The in vitro antimalarial ac-
tivities of nine structurally different HIV-1 protease inhibitors
have been compared herein (Fig. 1; Table 1), seven of which
are used clinically as antiretroviral drugs. As we have previ-
ously shown for the multidrug-resistant P. falciparum line Dd2
(51), the drug-sensitive line 3D7 is also sensitive to saquinavir
and ritonavir, with an EC50 similar to that obtained with Dd2
(Table 1). Both Dd2 and 3D7 displayed in vitro EC50 values for
atazanavir within clinically achievable drug plasma concentra-
tions in humans (Table 1), while lopinavir displayed antima-
larial activity well below achievable human plasma concentra-
tions for both parasite lines (Table 1). For the coformulation of
lopinavir and ritonavir, the EC50 with respect to the ritonavir
component was the same as that obtained for ritonavir alone,
whereas the EC50 of lopinavir, with respect to ritonavir, was
approximately fourfold higher. Two other structurally quite
distinct HIV-1 protease inhibitors, BR124 and BR314, which
show potent antiretroviral activity in vitro (56), were also found
to inhibit the growth of P. falciparum in vitro at comparable
concentrations (Table 1).
P. falciparum development and hemoglobin digestion. To
gain a better understanding of the effect of HIV aspartyl pro-
tease inhibitors on the development of P. falciparum, we ex-
amined the morphology and hemoglobin digestion pattern of
ring-stage parasites treated for 20 h with 10 M saquinavir,
ritonavir, atazanavir, E46, or pepstatin A or 1 M chloroquine.
While control parasites treated with DMSO all matured to the
trophozoite stage and contained regular arrays of hemozoin
TABLE 1. In vitro efficacy of antiretroviral drugs against P. falciparum
Compound
Antimalarial activity a (EC [M])
Anti-HIV
activity
(EC50 [M])
HIV-1
protease
inhibition
(Ki [nM])
Human
cathepsin D
IC50 (nM)
Log P
(pH 7.0)b
Concn in human
plasma
(Cmin–max [M])
Dd2 3D7
EC50 EC90 EC50 EC90
Saquinavir d 0.6 (0.2)m 2.7 (1.2) 1.2 (0.4) 3.0 (0.8) 0.002 1.4 (0.1) 	10,000 2.2 0.6–3.1c
Ritonavir e 0.8 (0.4)m 6.3 (4.7) 1.7 (0.6) 6.7 (3.0) 0.025 4.2 (0.5) 20 2.8 3.7–11.2c
Indinavir f 2.4 (1.4)m 	7 ND n ND 0.056 2.9 (0.4) 	10,000 1.6 0.21–11.1c
Lopinavir 1.0 (1.3) 2.5 (2.9) 3.3 (0.6) 4.8 (0.0) 0.017 0.04 ND 4.9 8.8–15.3c
Kaletra g
Ritonavir 0.8 (0.5) 1.4 (0.8) 1.5 (1.1) 2.2 (1.5) 0.025 4.2 (0.5) 20 2.8 0.1–0.7c
Lopinavir h 3.5 (2.0) 5.6 (4.3) 6.9 (5.2) 10.3 (6.7) 0.017 0.04 ND 4.9 8.8–15.3c
Atazanavir i 2.3 (0.5) 6.5 (0.7) 5.3 (1.1) 9.0 (0.4) 0.0014 2.7 (0.3) 	10,000 4.3 0.3–6.7
BR124 j 3.1 (0.1) 	10 ND ND 0.09 1.7 (0.5) 15,000 3.5 ND
BR314 j 3.7 (0.1) 	10 ND ND 0.06 0.6 (0.2) 1,000 3.9 ND
Amprenavir k 	10m ND ND ND 0.013 2.6 (0.6) 2.0 0.56–10.7
Nelfinavir l 	10m ND ND ND 0.014 3.3 (0.4) 435 4.3 1.7–7.0
a This work.
b Log P is predicted octanol solubility over water solubility and was calculated using the PrologD module within the computer program “Pallas for Windows version
2.1” (CompuDrug International Inc.). Log P 2 to 5 is considered necessary for good cell permeability (32).
c Human plasma Cmax–Cmin data from Mims Annual 2004 (8, 25).
d Reference 42. Saquinavir free base (Fortovase), 1,200 mg three times daily, or saquinavir mesylate (Invirase), 600 mg three times daily.
e Reference 28. Ritonavir (Norvir), 600 mg twice daily.
f Reference 57. Indinavir (Crixivan), 800 mg three times daily.
g Kaletra  lopinavir, 400 mg, together with ritonavir, 100 mg, twice daily, all with food.
h Reference 49. EC50 relative to ritonavir concentration in drug formulation.
i References 10, 36, and 43. Atazanavir (Reyataz), 400 mg once daily.
j Reference 56.
k Amprenavir (Agenerase), 1,200 mg twice daily.
l Nelfinavir (Viracept), 750 mg three times daily.
m Reference 51.
n ND, not determined.
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(Fig. 2A), parasites treated with chloroquine appeared stunted
and morphologically abnormal. As expected (44), hemoglobin
digestion was inhibited in chloroquine-treated parasites (Fig.
2B). Parasites treated with the cysteine protease inhibitor E64
or the aspartic protease inhibitor pepstatin A showed morphol-
ogies altered and distinct both from each other and from con-
trol parasites (Fig. 2A). E64-treated parasites in particular
showed food vacuole swelling, as has been previously reported
(5, 44). Consistent with previous findings (44), E64 inhibited
hemoglobin digestion in in vitro-cultured parasites (Fig. 2B)
while the hemoglobin digestion profile for pepstatin A-treated
parasites was similar to that for the DMSO control (Fig. 2B).
The morphology of ritonavir- and atazanavir-treated parasites
is clearly distinct from that of DMSO-treated control parasites
and from parasites treated with E64 and pepstatin. Although it
appears that these drugs cause enlargement of the digestive
vacuole, these effect cannot be clearly distinguished from non-
specific vacuolization of dying parasites, particularly given the
results of hemoglobin digestion experiments where a signifi-
cant reduction in total protein content in parasitized red blood
cells exposed to these drugs is apparent compared to DMSO-,
chloroquine-, E64-, and pepstatin A-treated cultures.
While similar hemoglobin digestion profiles were obtained
for both saquinavir and ritonavir-lopinavir (Fig. 2B), the effect
of these two inhibitors on parasite morphology appeared to be
different from that of either ritonavir or atazanavir. Treatment
with 10M saquinavir for 20 h resulted in parasites that appeared
pyknotic, a morphological appearance previously associated
with exposure to aspartic proteinase inhibitors (5, 46). Ritona-
vir-lopinavir killed all parasites (not shown), an expected find-
ing given that parasites treated with this combination were
exposed to 10 M ritonavir plus 46 M lopinavir.
Plasma concentrations of ARPIs in mice. Prior to investiga-
tion of the in vivo activity of ARPIs in a murine model of
malaria, the plasma concentrations of these drugs were mea-
sured in mice following the oral administration of different
doses of saquinavir, ritonavir, a combination of saquinavir and
ritonavir, or coformulated lopinavir-ritonavir (Table 2). Sa-
quinavir was not detected in the plasma of mice after admin-
istration of a 5-mg/kg dose. However, when saquinavir was
given at a dose of 10 mg/kg with the potent cytochrome P450
inhibitor ritonavir (5, 10, or 50 mg/kg), the plasma concentra-
tion of saquinavir exceeded the minimum target required for
suppression of HIV-1 replication in humans (Table 1) (4).
When saquinavir was administered at 10 mg/kg with 50-
mg/kg ritonavir, the plasma concentration of saquinavir was
lower than that obtained when administered with 10 mg/kg
ritonavir (Table 2; 1.3 versus 1.7 M). A similar effect has been
observed previously in rats and has been attributed to satura-
tion of the first-pass metabolism of saquinavir by excess ritona-
vir (29). The plasma concentration of ritonavir increased in a
dose-dependent manner when coadministered at 5, 10, and
50 mg/kg with 10-mg/kg saquinavir. However, higher ritonavir
concentrations were observed when the drug was administered
with less saquinavir (5-mg/kg saquinavir, 50-mg/kg ritonavir).
Interestingly, when ritonavir was administered at doses of 10
mg/kg or below, either alone or in combination with lopinavir,
no measurable ritonavir could be detected in the plasma of
FIG. 2. Effect of protease inhibitors on P. falciparum development
and hemoglobin digestion. Ring-stage in vitro-cultured Dd2-parasit-
ized erythrocytes were incubated for 20 h with either 1 M chloro-
quine or 10 M E64, pepstatin A (Pep), ritonavir (Rit), saquinavir
(Saq), atazanavir (Ataz), or ritonavir-lopinavir (Kaletra [Kal]). In par-
allel controls, parasites were treated with an equivalent concentration
of DMSO drug solvent. (A) Micrographs of representative Giemsa-
stained parasitized erythrocytes. (B) Effect of protease inhibitors on P.
falciparum hemoglobin hydrolysis (15% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis). Arrows indicate inhibition of hemo-
globin digestion by chloroquine (CQ; partial) and E64. RBC, unin-
fected red blood cells.
TABLE 2. Plasma concentrations of orally administered HIV-1
protease inhibitors in mice
Drug Dose(mg/kg)
Plasma concn (M)a
Saquinavir Ritonavir Lopinavir
Saquinavir 5 0
Ritonavir 10 0
50 10.1
Saquinavir-ritonavir 5/50 0.5 12.7
10/5 0.1 0
10/10 1.7 2.6
10/50 1.3 7.6
Lopinavir-ritonavir b 10/2.5 0 0
20/5 0 0.5
40/10 0 5.3
a Ritonavir, saquinavir, and lopinavir concentrations were measured from the
pooled plasma of three mice 4 hours after oral administration.
b Administered as lopinavir-ritonavir (Kaletra).
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mice. In contrast, when ritonavir was administered at a dose of
10 mg/kg in combination with 10-mg/kg saquinavir, a ritonavir
plasma concentration of 2.6 M was observed. A dose-depen-
dent increase in lopinavir concentration was observed in mice
administered the lopinavir-ritonavir coformulation (Table 2).
Antimalarial activity in vivo. The in vivo activity of the HIV-1
aspartyl protease inhibitors saquinavir, ritonavir, ritonavir-sa-
quinavir, and ritonavir-lopinavir was determined in a nonlethal
murine malaria model. Female C57BL/6J mice were infected
with 105 P. chabaudi AS-parasitized erythrocytes, and the an-
tiretroviral drugs, or vehicle control, were administered orally
twice daily for 8 consecutive days, starting 24 h postinfection.
Drug doses were selected based on plasma concentrations
achieved in mice (Table 2) and were as follows: 10 mg/kg
ritonavir, 10 mg/kg ritonavir-40 mg/kg lopinavir, 10 mg/kg each
ritonavir and saquinavir, and 10 mg/kg saquinavir.
The antiretroviral drug regimens most effective against P.
chabaudi AS infection were combinations of ritonavir-saquinavir
and ritonavir-lopinavir. Ritonavir-saquinavir, administered at
10-mg/kg doses, resulted in a reduction in the median peak
parasitemia (Fig. 3B; median peak parasitemia of 2% com-
pared to 20% in the vehicle control group; P  0.01), and a
2-day delay in the onset of parasitemia compared to the vehicle
control group was observed. Combined ritonavir (10 mg/kg)
and lopinavir (40 mg/kg) (administered as Kaletra) resulted in
a median peak parasitemia of 4% compared to the vehicle
control group median of 20% (P 
 0.004), as well as a 2-day
delay in the onset of parasitemia compared to the vehicle
FIG. 3. In vivo efficacy of HIV-1 protease inhibitors against murine
malaria. Female C57BL/6J mice infected with 105 P. chabaudi AS-
parasitized erythrocytes were treated orally, twice daily, for 8 consec-
utive days starting 24 h p.i. with either (A) vehicle, (B) 10 mg/kg each
ritonavir and saquinavir, (C) 10 mg/kg ritonavir and 40 mg/kg lopina-
vir, (D) 10 mg/kg ritonavir, or (E) 10 mg/kg saquinavir. Parasitemia
was monitored for 25 days from day 4 p.i. No parasitemia developed in
Malarone-treated mice (not shown).
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control group (Fig. 3A and C). Mice given ritonavir alone at a
dose of 10 mg/kg (Fig. 3D) also showed a significant reduction
in median peak parasitemia compared to the vehicle control
group (9% compared to 20% in the vehicle control group; P 
0.037). The course of parasitemia in those mice administered
saquinavir at a dose of 10 mg/kg did not differ from that
observed in vehicle-treated controls (Fig. 3A and E).
Comparison between active sites of P. falciparum and P.
chabaudi plasmepsins. Since the in vitro studies above were
conducted using the human-infecting P. falciparum parasite
while the in vivo studies were performed using the mouse-
infecting P. chabaudi parasite, we compared the structures of
their respective food vacuole aspartyl protease enzymes to
determine whether there is likely to be a significant difference
in drug binding between this rodent malaria digestive vacuole
plasmepsin and those of the human pathogen P. falciparum.
We found some important differences between the active
sites of the crystal structure (1lf3) of P. falciparum PfPM-II and
our homology model of P. chabaudi plasmepsin (PcPM) (Fig. 4).
In PfPM-II the S1, S2, and S1 subsites were generally smaller
than their equivalent pockets in PcPM (Fig. 4). At S1, PfPM-II
has a Phe residue at position 111, whereas in PcPM the equiv-
alent amino acid is leucine. Similarly, PfPM-II has a Leu at
residue 292 forming the S2 subsite, whereas PcPM has valine.
At S1 PfPM-II has positioned a Phe (residue number 294),
thus creating a smaller subsite than in PcPM, which has an Ile
in the same location. In addition, the polarity of the S3 and S3
subsites also differs between the two enzymes. At the S3 sub-
site, Asn 76 in PfPM-II is substituted for a Val in PcPM and at
S3 in PfPM-II (residue 114) a Thr is replaced by an Ile.
Comparison between active sites of P. falciparum plasmepsins
I, II, and IV. Overall, the active sites of PfPM-I and PfPM-II
are similar, differing mainly in the S1 subsite, which is much
larger in PfPM-I, the Phe 294 in PfPM-II being larger than the
corresponding Leu in PfPM-I. The active site substrate-binding
grooves of PfPM-I and PfPM-II are, however, significantly
different from that in PfPM-IV. For example, PfPM-II and
PfPM-IV have significant changes in polarity in the S3 and S3
pockets caused by the alterations of Thr 114 in PfPM-II to Ile
in PfPM-IV at the S3 pocket and the contributions of Met 75
and Asn 76 (PfPM-II) compared to Ser and Ile in PfPM-IV at
S3. The S2 and S1 subsites are also smaller in PfPM-II than in
PfPM-IV. The difference in the S2 subsite is due to the sub-
stitution of Leu 292 in PfPM-II for Val in PfPM-IV, and the
change in the S1 pocket is due to the substitution of Phe at
residue 111 (PfPM-II) for Leu in PfPM-IV. Changes are also
found in the S1 subsite as the replacement of Phe 294 and Val
78 with Ile and Gly, respectively, in PfPM-IV results in this
pocket being smaller in PfPM-II than in PfPM-IV. These vari-
ations suggest that PfPM-II has smaller subsites and is more
limiting in its capacity to accommodate ligands with bulky
substituents, and this can be seen experimentally using syn-
thetic inhibitors (61). Ligand docking studies below have fo-
cused principally on the active sites of PfPM-II and PfPM-IV,
for which there are crystal structures.
Comparison between ligand conformations bound to plas-
mepsin II and those bound to HIV-1 protease. Before docking
HIV protease inhibitors into plasmepsins, we compared and
analyzed known crystal structures of the HIV-1 protease in
complex with the ligands in Table 1 and compared them with
crystal structures of PfPM-II in complex with known ligands
(Fig. 5). In each case there was high conservation of an extended
beta-strand conformation for ligand backbones (RMSD, 0.78 Å
and 0.39 Å, respectively) and highly conserved ligand side
chain locations. This striking superimposition of these two sets
of protease-bound ligand conformations (Fig. 5, bottom) re-
veals high similarity in the aspartyl protease binding of the
ligands and supports the idea that HIV-1 protease ligands may
have affinity for PfPM-II.
Inhibition of PfPM-II and PfPM-IV enzymes. To validate
the hypothesis that plasmepsins may be targets of the ARPIs,
three inhibitors (saquinavir, ritonavir, and lopinavir) were as-
sayed against recombinant PfPM-II and PfPM-IV enzymes
(Table 3). Only one compound (saquinavir) showed submicro-
molar inhibitory potency against PfPM-II and PfPM-IV. The
other two compounds had low and similar IC50 values, reflect-
ing their similar structures. All of their IC50 concentrations are
below the levels achieved in individuals treated with these
drugs for HIV infection (Table 1), suggesting that they would
be active at the concentrations reached in vivo during antiretro-
viral therapy.
Docking of HIV protease inhibitors in P. falciparum plas-
mepsins II and IV. Initial validation of the ligand docking proto-
col was first performed (using the GOLD program) on the known
PfPM-II inhibitor EH58 (PDB code 1lf3) into PfPM-II and pep-
statin A into PfPM-IV (PDB code 1ls5). Docking results were
compared with the crystal structures and agreed best (PfPM-II:
RMSD, 0.63; PfPM-IV: RMSD, 0.73) when the modeling proto-
col incorporating all three (PfPM-II) or two (PfPM-IV) H-bond
restraints was used.
Using this validated modeling protocol, the three HIV pro-
tease inhibitors for which we have plasmepsin inhibition data
were docked into PfPM-II and PfPM-IV. Docked structures
for saquinavir, ritonavir (Fig. 6), and lopinavir were analyzed
for hydrogen bonding interactions, interaction energies, and
hydrophobic contacts using Ludi. The structural results suggest
that the hydrophobic and hydrogen bonding interactions be-
FIG. 4. Comparison of active sites of P. falciparum plasmepsin II
(PDB, 1LF3) and P. chabaudi plasmepsin (homology model) showing
side chain variations. Pepstatin A residues (P) are shown bound to P.
falciparum plasmepsin II binding sites (S). Prime and nonprime des-
ignations distinguish C-terminal from N-terminal sides of the cleavage
site. Subsite pocket residue differences in P. falciparum versus P.
chabaudi (residues in italics) are as follows: S4 (I290T), S3 (T114I), S2
(L292V), S1 (F111L), S1 (V78G; N76V), S2 (N76V) (all residues
numbered according to PfPM-II numbering).
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tween the drugs and HIV-1 protease are also possible with
PfPM-II and PfPM-IV.
EH58 had the highest predicted affinity for PfPM-II, far
greater than for saquinavir, while ritonavir and lopinavir had
about half the affinity of saquinavir. Lopinavir and ritonavir
had predicted affinities of approximately 1 M based on Ludi
values of about 600 for PfPM-II. These predicted affinities are
in reasonable agreement with experimentally determined in-
hibitory potencies from the enzyme assays. Both EH58 and
saquinavir have much higher hydrogen bonding scores than
ritonavir and lopinavir, the higher ranking for EH58 being
attributed to a better hydrophobic fit. Both EH58 and saquina-
vir are distinguished from the other two inhibitors in having
steric bulk at P3 and P1, which are complementary for the S3
and S1 pockets of PfPM-II.
For PfPM-IV, the single pepstatin A-bound crystal structure
(1ls5) has larger active-site S2, S1, and S1 pockets than the
corresponding pepstatin A-bound PfPM-II (1sme). The dock-
ing results for PfPM-IV (Table 3) show similar trends and
rankings as for PfPM-II, with saquinavir having higher affinity
than ritonavir or lopinavir. Pepstatin A ranked poorly due to
small side chains at P4, P3, P2, and P1 not optimally filling the
corresponding S4, S3, S2, and S1 pockets of PfPM-IV.
DISCUSSION
In this paper we have compared antimalarial activities of
nine HIV-1 protease inhibitors (Table 1). All compounds are
FIG. 5. Comparison of superimposed crystal structures of ligand-pro-
tease complexes (proteases not shown) for HIV-1 protease and P. falci-
parum plasmepsin II. (Top) Superimposition of crystal structures for HIV
protease inhibitor complexes showing protease-bound ligand conforma-
tions: lopinavir (PDB code, 1mui), indinavir (1hsg), ritonavir (1hxw),
amprenavir (1hpv), saquinavir (1hxb), nelfinavir (1ohr), BR124 (1d4l),
BR314 (1d4k). Overlay was performed using backbone atoms N, C, and
C (or equivalent) from P2-P1 using the Search and Compare module
within InsightII. (Middle) Superimposition of crystal structures for P.
falciparum PM-II inhibitor complexes showing protease-bound conforma-
tions: pepstatin A (1m43), pepstatin A (1sme), statine-based ligand
(1me6), rs367 (1lee), rs370 (1lf2), EH58 (1lf3). Overlay was performed
using backbone atoms N, C, and C (or equivalent) from P3-P1. (Bot-
tom) Superimposition of above enzyme-bound HIV-1 protease inhibitors
(black) on PfPM-II inhibitors (gray) using backbone atoms N, C, and C
(or equivalent) from P2-P1.
FIG. 6. Connolly surface of active site of PfPM-II (1lf3) in complex
with docked ritonavir showing enzyme subsites S3-S2.
TABLE 3. Enzyme inhibitory potencies and predicted relative
enzyme affinities (Ludi) for HIV-1 protease inhibitors
binding to PM-II and PM-IV
Plasmepsin
and drug IC50 (nM)
a Ludi scoreb Hbndc Lipod
PM-II
EH58 100 e 844 138 896
Saquinavir 750 748 110 796
Lopinavir 1,600 655 73 740
Ritonavir 1,250 587 50 792
PM-IV
Pepstatin A 1 521 157 763
Saquinavir 375 714 182 690
Lopinavir 	2,000 672 88 790
Ritonavir 1,800 653 181 711
a In vitro enzyme inhibition.
b Sum Ludi score  100 log Kd.
c Hbnd, hydrogen bond contribution to total binding energy.
d Lipo, hydrophobic interaction energy contribution. Rotational penalty scores
not shown.
e Reference 3.
VOL. 50, 2006 ANTIMALARIAL EFFICACY OF HIV PROTEASE INHIBITORS 645
potent in vitro antiviral agents against HIV-infected human
cells (EC50,
100 nM) and exhibit reasonable cell permeability
(log P, 1.6 to 4.9) (Table 1). Seven of the compounds exhibited
antimalarial activity between 0.5 and 4.0 M, while two drugs
(amprenavir and nelfinavir) showed minimal activity even at 10
M. The EC50 values obtained for the multidrug-resistant line
Dd2 (reference 51 and this study) are lower than those recently
reported (40); however, like the 3D7 EC50 values reported
here, they are either within or below levels achieved in clinical
use of these drugs (Table 1). The 90% effective concentration
values obtained for saquinavir, ritonavir, and lopinavir are also
within the target plasma range for these drugs in humans
receiving antiretroviral therapy. This is important as subthera-
peutic plasma levels of these drugs with respect to malaria may
lead to the selection of drug-resistant parasites. Investigation
of field isolates of P. falciparum from patients taking these
protease inhibitors as part of their antiretroviral therapy
should therefore be a priority in future studies. While further
work will be required to determine drug availability within
parasitized erythrocytes, another aspartyl protease inhibitor
displaying potent antimalarial activity (the pentapeptide pep-
statin A) has been shown to enter the parasite via a parasite-
induced permeation pathway (47). Of those inhibitors that
showed antimalarial activity in vitro, two were structurally
quite different macrocyclic compounds (26) that are highly
selective for HIV-1 protease over human aspartic proteases,
three were older ARPIs (saquinavir, ritonavir, and indinavir)
now in clinical use in humans for the treatment of HIV/AIDS,
and two were newer ARPIs (lopinavir-ritonavir [Kaletra] and
atazanavir) also in clinical use.
To investigate the potential clinical activity of ARPIs against
malaria, three of the HIV-1 protease inhibitors (saquinavir,
ritonavir, and lopinavir) were also evaluated in vivo for anti-
malarial efficacy in C57BL/6J mice infected with P. chabaudi
AS, a nonlethal murine model of malaria. P. chabaudi parasites
are known to have at least seven plasmepsin aspartic proteases
(35), one of which has similarity to the putative targets of HIV
protease inhibitors in P. falciparum, the digestive vacuole plas-
mepsins. Ritonavir alone and combined with saquinavir or
lopinavir significantly attenuated parasitemia, with the most
active regimen being a combination of ritonavir and saquinavir
or ritonavir and lopinavir (Fig. 3B and C). Whether this de-
crease in parasitemia is the result of a direct effect on parasite
growth or an indirect effect resulting from stimulation of the
hosts’ immune system remains to be determined. Saquinavir
given alone was ineffective, an expected finding given its poor
bioavailability when administered alone. Saquinavir is now
generally administered along with ritonavir, a potent cyto-
chrome P450 inhibitor (12), for so-called “boosting” to in-
crease the bioavailability of saquinavir. This benefit was also
reflected in the drug concentrations that we observed in the
plasma of mice after oral administration of a single dose of
saquinavir compared to when it was administered in combina-
tion with ritonavir (Table 2).
HIV-1 protease inhibitors also had significant effects on the
morphology of P. falciparum parasites and their hemoglobin
digestion. Treatment of ring-stage Dd2 parasites with 10 M
saquinavir resulted in pyknotic or dead parasites, an observa-
tion that has been made previously in parasites treated with P.
falciparum aspartic protease inhibitors such as pepstatin (5)
and SC-50083 (19). In contrast, after 20 h of treatment of
ring-stage parasites with ritonavir or atazanavir (10 M) a
distinct alteration, namely, vacuolar enlargement, was ob-
served, an appearance similar to that seen with the cysteine
protease inhibitor E64 (Fig. 2). It is not yet known whether this
is due to these drugs acting on digestive vacuole processes or
nonspecific vacuolization of dying parasites. Although we can-
not account for the differences in parasite morphology after
treatment with saquinavir versus ritonavir or atazanavir, it may
be that saquinavir exerts its effect more rapidly or perhaps acts
on a different parasite target. Similar morphological effects
have recently been observed for a geographically distinct drug-
sensitive line (HB3) treated with saquinavir (40).
We, and others, have previously hypothesized that the target
of ARPIs in the malaria parasite may be a family of P.
falciparum aspartyl proteases called PMs (40, 48, 51). It has
been reported that the PMs, together with cysteine proteinases
(falcipains), are involved in hemoglobin degradation by the
parasite, a process necessary for normal parasite growth and
development. The amino acids liberated by hemoglobin degrada-
tion, which occurs in the parasite digestive vacuole, are incor-
porated into parasite proteins with the released toxic heme
product polymerizing into inert, coordinated hematin dimers,
or hemozoin (15, 39, 53). It has also been suggested that
removal of hemoglobin provides space for the growing parasite
within the red blood cell (20).
P. falciparum has 10 PMs, two of which (PfPM-I and PfPM-
II) have been shown to be involved in the in vitro and in vivo
initiation of hemoglobin degradation in blood stages (6, 11, 18,
21–23), along with two further digestive vacuole plasmepsins
(histoaspartic proteinase [PfHAP] and PfPM-IV) that are also
thought to be involved in hemoglobin degradation (6, 7, 14,
61). Only one of the seven plasmepsins from P. chabaudi mu-
rine malaria, believed to be the hemoglobin-degrading aspartic
protease, appears to be equivalent to the P. falciparum diges-
tive vacuole enzymes with sequence identities to PM-I (48%),
PM-II (49%), and PM-IV (53%) (35). The enzymes involved in
this metabolic pathway, including PMs, are recognized targets
for new drug therapies (13, 45). However, given that individual
digestive vacuole plasmepsins of P. falciparum are not essential
for parasite survival (33, 38), it is unlikely that only a single P.
falciparum plasmepsin is the target for ARPIs (50).
Several experimental PIs have been shown to inhibit recom-
binant plasmepsin activity and parasite growth, including pep-
statin A (reviewed in reference 17). Other synthetic inhibitors,
such as Ro40-5576, produce Ki values of 6 nM, 250 nM, and 15
nM against PfPM-I, PfPM-II, and PfPM-IV, respectively (61).
Here we found that ritonavir, lopinavir, and saquinavir were
considerably less potent inhibitors of both PfPM-II and
PfPM-IV (Table 3) and also less potent than the nonspecific
tightly binding plasmepsin inhibitor pepstatin A (PfPM-II and
PfPM-IV Ki between 0.1 and 0.7 nM) (61). Our findings for
PfPM-II are consistent with another study showing that ritona-
vir and lopinavir inhibit recombinant PfPM-II activity in vitro
(ritonavir IC50, 3.1 M; lopinavir IC50, 2.7 M) (40).
As members of different families of the aspartic proteinases
(dimeric and monomeric), the HIV-1 protease and the plas-
mepsins share some similarities (54). Here we have performed
extensive modeling experiments with two digestive vacuole P.
falciparum plasmepsins and the equivalent P. chabaudi plas-
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mepsin to assess possible binding of HIV protease inhibitors to
plasmepsins involved in hemoglobin digestion by malaria par-
asites. The modeling experiments indicate that the dimensions
of the active site of P. falciparum PM-II are smaller and more
limiting than either PfPM-IV or the P. chaubaudi PM. This
may explain our findings that the ARPI combination of lopi-
navir-ritonavir was more active in vivo than ritonavir alone
against P. chabaudi, while no difference in activity of ritonavir
versus lopinavir-ritonavir was observed in vitro against P.
falciparum under the assay conditions used. Previous work
where cysteine protease inhibitors were evaluated as drugs
targeting degradation of hemoglobin in the digestive vacuole
also suggests that structural differences in target enzymes be-
tween rodent and human malarias may be critical consider-
ations when evaluating drug leads (31).
Our in silico experiments suggest that inhibitors of HIV-1
protease can fit the active sites of PfPM-II and PfPM-IV,
adopting very similar ligand backbone conformations, while
also positioning side chains in very similar locations. The active
sites of PfPM-II and PfPM-IV appear sufficiently flexible and
large enough to capture the HIV protease inhibitors investi-
gated herein, as well as more flexible and smaller inhibitors like
pepstatin A. It is therefore conceivable that their antimalarial
activities are due at least in part to inhibition of PfPMs. While
the HIV PIs do not fit as well as potent PM inhibitors such as
EH58 (Fig. 1), the predicted binding is consistent with the
observed micromolar activity in vitro against P. falciparum in
cell culture. Both PfPM-II and PfPM-IV clearly have a great
deal more space available at S3, S1, and S3 than can be
occupied by either the HIV protease inhibitors or most re-
ported PM inhibitors. As well, PfPM-IV has a significantly
larger S1 subsite than PfPM-II. Compounds with much bulk-
ier substituents would therefore be predicted to have higher
affinities for PMs. Our in vitro antimalarial studies and mea-
sured versus predicted ligand affinities for PfPM-II and
PfPM-IV support the possible involvement of plasmepsins in
the action of these drugs.
The observed inhibitory activity of ARPIs against malaria
parasites, P. falciparum in vitro and P. chabaudi in vivo, raises
the prospect of their potential antimalarial benefit in HIV- and
malaria-coinfected individuals. They have the advantage over
new experimental antimalarial agents in development as they
are already clinically accepted drugs that are widely prescribed
for treatment of HIV/AIDS. Although they are expensive for
people in the developing world, multinational agreements in
recent years have provided much greater access to these drugs
in regions where HIV and P. falciparum are both endemic.
However, to better determine the antimalarial potential of
these drugs, further studies are required, including clinical
trials, parasite resistance studies, and pharmacodynamic inves-
tigations on interactions with existing antimalarial therapies.
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